

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 March 2018 (22.03.2018)



(10) International Publication Number
WO 2018/052556 A1

(51) International Patent Classification:
C07K 16/00 (2006.01) *A61K 39/00* (2006.01)
C07K 16/10 (2006.01)

(21) International Application Number:
PCT/US2017/045126

(22) International Filing Date:
02 August 2017 (02.08.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/370,201 02 August 2016 (02.08.2016) US
62/485,671 14 April 2017 (14.04.2017) US

(71) Applicant: **VISTERRA, INC.** [US/US]; One Kendal
Square, Suite B3301, Building 300, 3rd Floor, Cambridge,
MA 02139 (US).

(72) Inventors: **VISWANATHAN, Karthik**; 1 John Swift
Road, Acton, MA 01720 (US). **RAMAKRISHNAN,
Boopathy**; 605 Middle Street, Unit 19, Braintree, MA
02184 (US). **BOOTH, Brian**; 99 Cass Street, West Rox-
bury, MA 02132 (US). **NARAYAN, Kristin**; 150 Maple
St., Lexington, MA 02420 (US). **WOLLACOTT, Andrew,
M.**; 16 Woodchester Drive, Milton, MA 02186 (US).

(74) Agent: **COLLAZO, Diana, M.**; Lando & Anastadi, LLP,
Riverfront Office Park, One Main Street, Suite 1100, Cam-
bridge, MA 02142 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

(54) Title: ENGINEERED POLYPEPTIDES AND USES THEREOF




FIG. 1

(57) Abstract: Polypeptides, such as antibody molecules and fusion proteins, comprising an Fc region, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders. In particular, Fc regions comprising either one or multiple mutations selected from the particular mutations disclosed in Table 1 are disclosed. Certain of said mutations result in increased affinity for the neonatal Fc receptor (FcRn), and certain of said mutations result in enhanced half-life of engineered antibodies and also have an impact on effector functions. Particular disclosed mutations are M252Y, S254T, T256E, L309N, T250Q, M428L, N434S, N434A, T307A, E380A, N434A, M252Y, S254T, T256E, or a combination thereof as e.g. T256D/Q311V/A378V, H285N/ T307Q/N315D, H285D/T307Q/A378V, T307Q/Q311V/A378V, T256D/ N286D/T307R/Q311V/A378V, or T256D/T307R/Q311.

[Continued on next page]

WO 2018/052556 A1

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (*Art. 21(3)*)
- with sequence listing part of description (*Rule 5.2(a)*)